Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects
Clinical Pharmacology in Drug Development · 2024-04 · 13 (4) · 389-403
DOI: 10.1002/cpdd.1358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 08.01.2024. Verfasst von Susanne Bonsmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: AiCuris Anti-infective Cures AG, Wuppertal, Germany. Hauptthemen laut MEDLINE: Glucuronides, Sulfonamides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pritelivir is a helicase‐primase inhibitor active against HSV. Two human mass balance trials (a multiple‐dose trial and a single‐dose trial) were performed to characterize the absorption, distribution, metabolism, and excretion of 100 mg oral pritelivir combined with a single microdose of 14 C‐pritelivir. Blood, urine, and feces samples were collected up to 26 days postdose. The plasma half‐life of pritelivir was 63‐67 hours. Overall, 92% and 66% of the administered dose was recovered in the multiple and single dose trials, respectively. The low recovery after the single dose (66%) was most likely related to the formulation used. The major metabolic pathway was amide hydrolysis leading to amino thiazole sulfonamide (ATS) and pyridinyl phenyl acetic acid (PPA). In plasma, pritelivir, ATS, PPA, and PPA‐acyl glucuronide accounted for 40.6%, 9.4%, 5.1%, and 0.2% of total radioactivity. More than 90% of drug‐related material was eliminated 624 hours postdose. The majority was excreted in urine (75% and 77%), followed by feces (16% and 23%). The main components in urine were PPA‐acyl glucuronide (and its isomers), ATS, and its N‐demethylated isomers. Only minor metabolites were observed in feces. In conclusion, the major metabolic pathways of pritelivir have been identified with the primary excretion route being renal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AiCuris Anti-infective Cures AG, Wuppertal, Germany.
- Aicuris Anti-infective Cures AG (Retired), Wuppertal, Germany.
- Present affiliation: BioNTech SE, Mainz, Germany.
- Molenpad ClinPharm Support, Weesp, The Netherlands.
Zitieren
APA
Bonsmann, S., McCormick, D., Pausch, J., de Vries, M., Sumner, M., Birkmann, A., Zimmermann, H., & Kropeit, D. (2024). Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects. Clinical Pharmacology in Drug Development, 13(4), 389-403. https://doi.org/10.1002/cpdd.1358
Vancouver
Bonsmann S, McCormick D, Pausch J, de Vries M, Sumner M, Birkmann A, et al. Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects. Clinical Pharmacology in Drug Development. 2024;13(4):389-403. doi:10.1002/cpdd.1358
BibTeX
@article{Bonsmann2024,
author = {Bonsmann, Susanne and McCormick, David and Pausch, Jörg and de Vries, Michiel and Sumner, Melanie and Birkmann, Alexander and Zimmermann, Holger and Kropeit, Dirk},
title = {Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {4},
pages = {389--403},
doi = {10.1002/cpdd.1358}
}
EUVIMED